Last edition
News about "RemeGen "
Remegen Partners with Santen To Commercialise RC28-E in Greater China and Asian Countries
RemeGen, a leading Chinese biopharmaceutical company, has entered into an exclusive licensing agreement for the ophthalmic innovative drug RC28-E with Santen China, a wholly-owned subsidiary of Santen Pharmaceutical.
RemeGen | 19/08/2025 | By Dineshwori | 139
FDA Grants FTD to RemeGen Telitacicept for Treatment of pSS
RemeGen Co. Ltd. Has received Fast Track Designation (FTD) by the US Food and Drug Administration (FDA) for its innovative BLyS/APRIL dual-target fusion protein drug.
RemeGen | 03/04/2024 | By Aishwarya | 431
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy